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Lazaroid U74006F for Canine Small Bowel Preservation 
N. Hamada, S. Zhang, M. Nomoto, Y. Zhu, A. Nemoto, Y. Kawashima, T.E. Starzl, and S. Todo 
L AZARO IDS are a new group of synthetic 21-amino-
steroids that inhibit iron-dependent lipid peroxidation 
without steroid action. 1 It has been known that lazaroids 
protect various organs from ischemic and reperfusion inju-
ry.2-4 The aim of this study was to determine if one of the 
lazaroid compounds, U74006F, is effective for canine small 
bowel preservation. 
MATERIALS AND METHODS 
Adults mongrel dogs, weighing from 18 to 24 kg, were used. The 
entire small bowel was procured and flushed with cold lactated 
Ringer's solution containing heparin through the superior mesen-
teric artery. The intestinal lumen was also irrigated with the same 
solution. After the graft was preserved in the cold lactated Ringer's 
,olution for 24 hours, it was transplanted orthotopically into the 
,;ame animal. The U74006F was intravenously administered at a 
dose of 0 mg/kg (Laz(O», 5 mg/kg (Laz(5», 10 mglkg (Laz(10», or 
15 mg/kg (Laz( 15» 30 minutes before graft removal and 30 
minutes before graft reperfusion. Five animals were randomly 
tested at each group. For histological examination and biochemical 
determinations including maltase, malondialdehyde (MDA), my-
eloperoxidase (MPO), phospholipids (PL), and energy charge 
(EC), short segments of the ileum were collected before procure-
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ment, immediately after vascular flushing, at the end of 24-hour 
preservation, and 15 minutes and 1 hour after graft reperfusion. 
RESULTS 
Compared to the no-treatment group, lazaroid U74006F 
treatment suppressed the loss of maltase (Fig IA), MDA 
production (Fig IB), MPO activity (Fig IC), and PL 
degradation (Fig 10), and regained significantly higher EC 
after graft reperfusion. Structural alterations developed in 
the ileal mucosa after graft reperfusion, including denuda-
tion or sloughing of the mucosa, hemorrhage, neutrophil 
accumulation, and deep crypt cell necrosis. These changes 
were more evident with the no-treatment group than the 
groups treated by lazaroids. 
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Fig 1.' Changes of maltase ac-
tivity (A), MDA (8), MPO (e) • 
and total PL (0) in the indicated 
groups at 1 hour after reperfu-
sion. Values are expressed 
means ~ SEM. 'p < .05 vs 
Laz(O); "P < .05 vs control. 
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CONCLUSION 
Lazaroids are potent inhibitors of iron-dependent lipid 
peroxidation and have been shown to be beneficial in a 
various organs for ischemic reperfusion injury.2-4 In this 
study, after small bowel reperfusion, lazaroid U74006F was 
found to ameliorate villus enzyme loss (Maltase), to inhibit 
lipid peroxidation (MDA), to decrease neutrophil infiltra-
tion (MPO), to reduce phospholipid degradation, and to 
enhance energy charge. Lazaroid U74006F treatment also 
demonstrated the less histological damage than did the 
no-treatment group. Thus, our study confirms that lazaroid 
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U74006F is effective for protection of the canine small 
bowel from preservation and reperfusion injury. 
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